Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)
Journal of Clinical Oncology · 20.10.2024 · 42 (30) · 3606-3617
DOI: 10.1200/jco.23.02668 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.10.2024. Verfasst von Luke R G Pike und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Protein Kinase Inhibitors, Anaplastic Lymphoma Kinase, ErbB Receptors. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
PURPOSE Newer-generation tyrosine kinase inhibitors (TKIs) for non–small cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR ) mutations and anaplastic lymphoma kinase ( ALK ) rearrangements have demonstrated high CNS activity. The optimal use of up-front stereotactic radiosurgery (SRS) for brain metastases (BM) in patients eligible for CNS-penetrant TKIs is controversial, and data to guide patient management are limited. MATERIALS AND METHODS Data on TKI-naïve patients with EGFR- and ALK-driven NSCLC with BM treated with CNS-penetrant TKIs with and without up-front SRS were retrospectively collected from seven academic centers in the United States. Time-to-CNS progression and overall survival (OS) were analyzed, with multivariable adjustment in Fine & Gray and Cox proportional hazards models for clinically relevant factors. RESULTS From 2013 to 2022, 317 patients were identified (200 TKI-only and 117 TKI + SRS). Two hundred fifty (79%) and 61 (19%) patients received osimertinib and alectinib, respectively. Patients receiving TKI + SRS were more likely to have BM ≥1 cm ( P < .001) and neurologic symptoms ( P < .001) at presentation. Median OS was similar between the TKI and TKI + SRS groups (median 41 v 40 months, respectively; P = .5). On multivariable analysis, TKI + SRS was associated with a significant improvement in time-to-CNS progression (hazard ratio [HR], 0.63 [95% CI, 0.42 to 0.96]; P = .033). Local CNS control was significantly improved with TKI + SRS (HR, 0.30 [95% CI, 0.16 to 0.55]; P < .001), whereas no significant differences were observed in distant CNS control. Subgroup analyses demonstrated a greater benefit from TKI + SRS in patients with BM ≥1 cm in diameter for time-to-CNS progression and CNS progression-free survival. CONCLUSION The addition of up-front SRS to CNS-penetrant TKI improved time-to-CNS progression and local CNS control, but not OS, in patients with BM from EGFR - and ALK-driven NSCLC. Patients with larger BM (≥1 cm) may benefit the most from up-front SRS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
- Albert Einstein College of Medicine, Bronx, NY.
- Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
- Division of Hematology and Oncology, Department of Medicine, University of Colorado, Aurora, CO.
- Division of Hematology and Oncology, Department of Medicine, Stanford University, Palo Alto, CA.
- Department of Radiation Oncology, Stanford University, Palo Alto, CA.
ORCID-Profile: Luke R G Pike, Emily Miao, Lillian A Boe, Tejas Patil, Brandon S Imber, Veronica Chiang, Sarah B Goldberg, Joshua D Palmer, Rahul N Prasad, Tony J C Wang, Catherine A Shu, Lanyi Nora Chen, Nicholas J Thomas, Steve E Braunstein, Brian D Kavanagh, D Ross Camidge, Chad G Rusthoven
Förderung
- NCI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Pike, L. R. G., Miao, E., Boe, L. A., Patil, T., Imber, B. S., Myall, N. J., Pollom, E. L., Hui, C., Qu, V., Langston, J., Chiang, V., Grant, M., Goldberg, S. B., Palmer, J. D., Prasad, R. N., Wang, T. J. C., Lee, A., Shu, C. A., Chen, L. N., …, & Rusthoven, C. G. (2024). Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC). Journal of Clinical Oncology, 42(30), 3606-3617. https://doi.org/10.1200/jco.23.02668
Vancouver
Pike LRG, Miao E, Boe LA, Patil T, Imber BS, Myall NJ, et al. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC). Journal of Clinical Oncology. 2024;42(30):3606-3617. doi:10.1200/jco.23.02668
BibTeX
@article{Pike2024,
author = {Pike, Luke R G and Miao, Emily and Boe, Lillian A and Patil, Tejas and Imber, Brandon S and Myall, Nathaniel J and Pollom, Erqi L and Hui, Caressa and Qu, Vera and Langston, Jacob and Chiang, Veronica and Grant, Michael and Goldberg, Sarah B and Palmer, Joshua D and Prasad, Rahul N and Wang, Tony J C and Lee, Albert and Shu, Catherine A and Chen, Lanyi Nora and Thomas, Nicholas J and Braunstein, Steve E and Kavanagh, Brian D and Camidge, D Ross and Rusthoven, Chad G},
title = {Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {30},
pages = {3606--3617},
doi = {10.1200/jco.23.02668}
}
EUVIMED